NCT05638763 2022-12-06
Cytochrome P450 Inhibition to Decrease Dosage of Dasatinib for Chronic Myelogenous Leukemia
Hospital Universitario Dr. Jose E. Gonzalez
Phase 2 Unknown
Clinical Trials
12 trialsNCT04578847 2020-10-08
READIT
National Research Center for Hematology, Russia
Phase 2 Unknown
NCT02638428 2020-03-19
Genomics-Based Target Therapy for Children With Relapsed or Refractory Malignancy
Samsung Medical Center
Phase 2 Unknown
NCT04284202 2020-02-25
PD-1 Combined With Dasatinib for as Third-line Treatment for ARID1A Mutation Advanced NSCLC
The Affiliated Hospital of Qingdao University
Phase 2 Unknown
NCT02268370 2019-11-29
TRAD
University Health Network, Toronto
Phase 2 Unknown
NCT02233049 2018-07-23
BIOMEDE
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2 Unknown
NCT02744768 2018-03-22
D-ALBA Frontline Sequential Dasatinib and Blinatumomab in Adult Philadelphia Positive Acute Lymphoblastic Leukemia
Gruppo Italiano Malattie EMatologiche dell'Adulto
Phase 2 Unknown
NCT01802450 2015-09-17
DASAPOST
PETHEMA Foundation
Phase 2 Unknown
NCT01887561 2013-06-27
Dasatinib for Patients Achieving Complete Molecular Response for Cure D-NewS Trial
Kanto CML Study Group
Phase 2 Unknown
NCT01051115 2011-08-31
D'ACCORD
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Phase 2 Unknown
NCT00112775 2011-06-07
BMS-354825 or Imatinib Mesylate in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia That Did Not Respond to Previous Imatinib Mesylate
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00979160 2009-09-18
Evaluation of Response of Dasatinib to Treat Mastocytosis
Federico II University
Phase 2 Unknown